Evidence map›Paper›PMID 39295098›Full record

ReviewCNS neuroscience & therapeutics2024

Revisiting dezocine for opioid use disorder: A narrative review of its potential abuse liability.

Gordon A Barr, Heath D Schmidt, Ashish P Thakrar, Henry R Kranzler, Renyu Liu

Abstract readReview
In one paragraph

Review in CNS neuroscience & therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Dezocine and Addiction: Friend or Foe?Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gordon A BarrDepartment of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-4751-9937
Heath D SchmidtDepartment of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ashish P ThakrarDivision of General Internal Medicine, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Henry R KranzlerDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Renyu LiuDepartment of Anesthesiology and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0001-9335-8981

Funding

The role of central GLP-1 receptors in animal models of cocaine addictionR01DA037897 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI SCHMIDT, HEATH D · 2015 to 2023
$3.5M
Water soluble variants of the human mu opioid receptorR01GM111421 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI LIU, RENYU · 2014 to 2018
$1.7M
Rapid outpatient low-dose initiation of buprenorphine for individuals with OUD using fentanylR34DA057507 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI KAMPMAN, KYLE MATTHEW, THAKRAR, ASHISH PRAKASH · 2023 to 2025
$690k
Single-nucleus transcriptomics in rat striatum following morphine administration and withdrawalR21DA057458 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI CRIST, RICHARD C., SCHMIDT, HEATH D · 2023 to 2024
$447k
NIDA NIH HHS R01 DA037897NIDA NIH HHS R21 DA057458NIDA NIH HHS R34 DA057507NIGMS NIH HHS R01 GM111421
6 · The paper itself

Abstract

aimsOpioid use disorder (OUD) remains a serious public health problem. Opioid maintenance treatment is effective but under-utilized, hard to access under existing federal regulations, and, once patients achieve OUD stability, challenging to discontinue. Fewer than 2% of persons with OUD stop using opioids completely. There have been calls from public advocacy groups, governmental agencies, and public health officials for new treatments for OUD. Dezocine, a non-scheduled opioid previously used in the United States and currently widely prescribed in China for pain management, could be a candidate for a novel OUD treatment medication in the U.S. Nonetheless, to date, there have been no reviews of the clinical and preclinical literature detailing dezocine's abuse potential, a key consideration in assessing its clinical utility. DISCUSSION: There are no English language reports of human abuse, dependence, or overdose of dezocine, despite years of extensive clinical use. There are a few case reports of dezocine abuse in the Chinese literature, but there are no reports of overdose deaths. Dezocine is perceived as an opioid and is "liked" by opioid-experienced human and non-human primates, properties that are not dose-dependent and are mitigated by ceiling effects-higher doses do not result in more "liking." There is little withdrawal, spontaneous or precipitated, in humans, monkeys, rats, or mice treated chronically with dezocine alone. However, at some doses, dezocine can precipitate withdrawal in humans and monkeys dependent on other opioids. In rodents, dezocine reduces the severity of morphine withdrawal and the rewarding properties of other opioids.

conclusionsAlthough dezocine is reinforcing in humans and monkeys with prior or concurrent opioid use within a restricted dose range, there are only a few anecdotal reports of dezocine abuse despite of the long history of use in humans. Given the evidence of dezocine's limited abuse potential, it could be useful both as a treatment for OUD. However, in-depth studies would be required for dezocine to be re-considered for clinical use.

Indexed as

Opioid-Related DisordersAnalgesics, OpioidAnimalsBridged Bicyclo Compounds, HeterocyclicHumansTetrahydronaphthalenesAnalgesics, OpioidBridged Bicyclo Compounds, HeterocyclicdezocineTetrahydronaphthalenesbiased mu‐opioid liganddependencedezocinedrug discriminationdrug self‐administrationopioid use disorder

Identifiers

PMID39295098
PMCPMC11410865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.